Inocras and D3b Launch Collaborative Research to Decode Rare Sinonasal Cancer Genetics
Key Insights
Inocras (search) and the Center for Data Driven Discovery in Biomedicine (search) (D3b (search)) have signed a collaborative agreement to advance research on rare sinonasal cancers through Whole Genome Sequencing and bioinformatic analysis.
The initial phase will analyze 30 sinonasal mucosal melanoma (search) cases, including both tumor and germline samples, to generate comprehensive genetic data that could inform new therapeutic approaches.
This partnership, part of the CORSICA (search) Project spanning 10 research sites nationwide, aims to establish genomic sequencing as a standard of care for sinonasal cancers and contribute to multiple scientific publications.
Inocras (search), an AI-driven genomics company, has partnered with the Center for Data Driven Discovery in Biomedicine (search) (D3b (search)) in a groundbreaking collaborative research agreement focused on advancing the understanding of rare sinonasal cancers. Announced on April 21, 2025, the partnership will leverage Inocras's expertise in Whole Genome Sequencing (WGS) and bioinformatic analysis to examine rare sinonasal cancer (search) samples provided by D3b.
The collaboration forms part of the Cole-Reagins Registry for Sinonasal Cancer (search) (CORSICA (search)) Project, a translational research initiative funded by the Natalie A. Cole-Reagins Family Foundation. CORSICA aims to improve the study and treatment of sinonasal cancer by connecting biospecimens with clinical registry data to track long-term patient outcomes across 10 research sites throughout the United States.
Targeting Sinonasal Mucosal Melanoma
The initial phase of the collaboration will focus on performing WGS and bioinformatic analysis on 30 sinonasal mucosal melanoma (search) cases. Each case will include both tumor and germline samples, enabling researchers to generate comprehensive genomic data and CancerVision (search)™ reports that could provide deeper insights into the genetic foundations of this rare cancer type.
Sinonasal cancers remain particularly challenging to diagnose and treat due to their rarity, making this research especially valuable to the medical community. These cancers affect the nasal cavity and paranasal sinuses, with mucosal melanoma being one of the most aggressive subtypes.
Dr. Garret W. Choby, Associate Professor of Otolaryngology – Head and Neck Surgery and Neurological Surgery at the University of Pittsburgh School of Medicine, emphasized the significance of the partnership: "We hope that this partnership represents a significant step forward in our understanding of the genetic underpinnings of sinonasal cancers. By leveraging advanced genomics and bioinformatics, we aim to uncover critical genetic insights that could ultimately inform new therapeutic strategies for our patients."
Leadership and Collaboration Structure
The D3b (search) leadership team spearheading this collaboration includes Phillip "Jay" Storm, Adam Resnick, and Jena Lilly, who are working alongside researchers from prestigious academic and medical institutions as part of the CORSICA (search) Project.
The research findings are expected to contribute to multiple shared publications, presentations, and scientific posters, furthering knowledge in this understudied area of oncology. Beyond the immediate research goals, this initiative establishes a framework for future collaborations between Inocras (search), D3b (search), CORSICA (search), and other academic institutions.
Long-term Vision for Precision Medicine
The ultimate goal of this partnership extends beyond the initial research phase. The collaborators aim to establish WGS and bioinformatics-driven insights as a standard of care for mucosal melanomas and other sinonasal cancers, potentially transforming how these rare cancers are diagnosed and treated.
Inocras (search), which specializes in delivering critical insights to cancer and rare disease patients through whole genome sequencing and bioinformatics, brings significant technological capabilities to the partnership. The company offers whole genome testing products including CancerVision (search), RareVision (search), and MRDVision (search) through its CAP/CLIA certified laboratory, powered by a proprietary bioinformatics pipeline.
This collaboration represents a significant step forward in applying precision medicine approaches to rare cancers that have historically received less research attention than more common malignancies. By combining clinical expertise with advanced genomic analysis, the partnership aims to unlock new possibilities for patients with these challenging-to-treat conditions.